- Home
- LYEL
as of 12-05-2025 4:00pm EST
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 369.4M | IPO Year: | 2021 |
| Target Price: | $16.67 | AVG Volume (30 days): | 44.4K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -21.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.65 - $25.74 | Next Earning Date: | 11-12-2025 |
| Revenue: | $41,000 | Revenue Growth: | -34.92% |
| Revenue Growth (this year): | -62.38% | Revenue Growth (next year): | N/A |
AI-Powered LYEL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Lyell Immunopharma Inc. (LYEL)
Chief Operating Officer
Avg Cost/Share
$16.12
Shares
95
Total Value
$1,531.40
Owned After
15,750
SEC Form 4
President and CEO
Avg Cost/Share
$16.11
Shares
412
Total Value
$6,637.32
Owned After
67,159
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$16.16
Shares
138
Total Value
$2,230.08
Owned After
15,366
SEC Form 4
VP, Corporate Controller
Avg Cost/Share
$16.10
Shares
239
Total Value
$3,847.90
Owned After
9,213
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hill Stephen J. | LYEL | Chief Operating Officer | Nov 10, 2025 | Sell | $16.12 | 95 | $1,531.40 | 15,750 | |
| Seely Lynn | LYEL | President and CEO | Nov 10, 2025 | Sell | $16.11 | 412 | $6,637.32 | 67,159 | |
| Lee Gary K. | LYEL | Chief Scientific Officer | Nov 10, 2025 | Sell | $16.16 | 138 | $2,230.08 | 15,366 | |
| Bulis Veronica Sanchez | LYEL | VP, Corporate Controller | Nov 10, 2025 | Sell | $16.10 | 239 | $3,847.90 | 9,213 |
Compare LYEL vs Leading Stocks
See how LYEL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.